Table 7.

Pharmacokinetic properties of the two screened peptides and two FDA-approved protease inhibitors including Ritonavir and Lopinavir as control compounds.

Part B	2ERW-9	1KJ0-7	Lopinavir	Ritonavir
Human Intestinal Absorption	–	–	+	+
Blood Brain Barrier	+	+	+	–
Plasma protein binding (100%)	0.42	0.127	1.157	1.113
Water solubility (LogS)	−3.308	−2.702	−3.414	−3.225
Estrogen receptor binding	+	+	+	+
Androgen receptor binding	+	+	+	+
Thyroid receptor binding	+	+	+	+
Glucocorticoid receptor binding	+	–	+	+
Aromatase binding	+	+	–	+
PPAR gamma	+	+	+	+
Subcellular localization	Mitochondria	Mitochondria	Mitochondria	Lysosomes
Caco-2 Permeability	–	–	+	+
OATP2B1 inhibitior	–	–	+	+
OATP1B1 inhibitior	+	+	+	+
OATP1B3 inhibitior	+	+	+	+
MATE1 inhibitior	–	–	–	–
OCT2 inhibitior	–	–	–	–
BSEP inhibitior	+	+	+	+
P-glycoprotein inhibitior	+	+	+	+
P-glycoprotein substrate	+	+	+	+
CYP3A4 substrate	+	+	+	+
CYP2C9 substrate	–	–	–	+
CYP2D6 substrate	–	–	–	–
CYP3A4 inhibition	–	–	–	+
CYP2C9 inhibition	–	–	–	–
CYP2C19 inhibition	–	–	–	+
CYP2D6 inhibition	–	–	–	–
CYP1A2 inhibition	–	–	–	–
CYP inhibitory promiscuity	–	–	–	+
UGT catelyzed	–	–	–	–